Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors

US10975088B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Andrew W. Buesking · Wilmington, US
• Richard B. Sparks · Linwood, US
• Andrew P. Combs · Kennett Square, US
• Brent Douty · Coatesville, US
• Nikoo Falahatpisheh · Wilmington, US
• Lixin Shao · Wilmington, US
• Stacey Shepard · Wilmington, US
• Eddy W. Yue · Landenberg, US
• Artem Shvartsbart · Kennett Square, US
• David M. Burns · Woodbury, US
• Daniel Levy · San Mateo, US

Key dates

• Filing date: Oct 2, 2019
• Grant date: Apr 13, 2021
• Expiry date: Oct 2, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.